Publique en esta revista
Información de la revista
Vol. 6. Núm. H.
Avances en el tratamiento antitrombótico en el intervencionismo coronario percutáneo
Páginas 2H-10H (Octubre 2006)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 6. Núm. H.
Avances en el tratamiento antitrombótico en el intervencionismo coronario percutáneo
Páginas 2H-10H (Octubre 2006)
Avances en el tratamiento antitrombótico en el intervencionismo coronario percutáneo
DOI: 10.1016/S1131-3587(06)74839-7
Acceso a texto completo
Mecanismo de acción de los fármacos antitrombóticos
Mechanism of Action of Antithrombotic Drugs
Visitas
...
Dabit Arzamendi, Xavier Freixa, Maria Puig, Magda Heras??
Autor para correspondencia
mheras@clinic.ub.es

Correspondencia: Dra. M. Heras. Servicio de Cardiología. Hospital Clínic. IDIBAPS. Villarroel, 170. 08036 Barcelona. España.
Servicio de Cardiología. Hospital Clínic. IDIBAPS. Barcelona. España
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas

Los fármacos antiplaquetarios y anticoagulantes desempeñan un papel fundamental en el tratamiento de los síndromes coronarios agudos, ya que la trombosis coronaria es el proceso que los desencadena. A su vez, el intervencionismo coronario percutáneo, el tratamiento de elección en un gran porcentaje de pacientes con este síndrome, supone también un potente estímulo para la activación de las plaquetas y de la coagulación.

En este artículo se describe brevemente la activación y agregación plaquetarias y la activación de la coagulación. También se analizan los fármacos antitrombóticos utilizados en el intervencionismo coronario percutáneo y se describen sus mecanismos de acción, dosis, indicaciones y efectos secundarios, en pacientes con cardiopatía estable e inestable.

Palabras clave:
Aspirina
Ticlopidina
Clopidogrel
Antagonistas de los receptores de la glucoproteína IIb/IIIa
Heparina
Bivalirudina

Since acute coronary syndrome results from coronary thrombosis, antiplatelet and anticoagulant drugs play a fundamental role in its treatment. Moreover, percutaneous coronary intervention, the preferred form of treatment in a large percentage of patients with this syndrome, is also a potent stimulator of platelet activation and blood coagulation. In this article, the mechanisms of platelet adhesion and aggregation and of blood coagulation are reviewed briefly. In addition, there is also a review of the antithrombotic drugs used in percutaneous coronary intervention, which includes their mechanisms of action, dosages, indications, and side-effects in patients with both stable and unstable coronary artery disease.

Key words:
Aspirin
Ticlopidine
Clopidogrel
Glycoprotein IIb/IIIa antagonist
Heparin
Bivalirudin
El Texto completo está disponible en PDF
Bibliografía
[1.]
G.Y. Lip, A. Blann.
Von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?.
Cardiovasc Res, 34 (1997), pp. 255-265
[2.]
K. Jurk, K.J. Clemetson, P.G. De Groot, M.F. Brodde, M. Steiner, N. Savion, et al.
Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor.
Faseb J, 17 (2003), pp. 1490-1492
[3.]
P. Golino, A. Ravera, M. Ragni, P. Cirillo, O. Piro, M. Chiariello.
Involvement of tissue factor pathway inhibitor in the coronary circulation of patients with acute coronary syndromes.
Circulation, 108 (2003), pp. 2864-2869
[4.]
J. Steffel, T.F. Luscher, F.C. Tanner.
Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications.
Circulation, 113 (2006), pp. 722-731
[5.]
C. Patrono, L.A. García Rodríguez, R. Landolfi, C. Baigent.
Lowdose aspirin for the prevention of atherothrombosis.
N Engl J Med, 353 (2005), pp. 2373-2383
[6.]
M.W. Behan, R.F. Storey.
Antiplatelet therapy in cardiovascular disease.
Postgrad Med J, 80 (2004), pp. 155-164
[7.]
E.H. Awtry, J. Loscalzo.
Aspirin.
Circulation, 101 (2000), pp. 1206-1218
[8.]
L. López Bescós, F. Arós Borau, R.M. Lidon Corbi, A. Cequier Fillat, H. Bueno, J.J. Alonso, et al.
Actualización (2002) de las Guías de Práctica Clínica de la Sociedad Española de Cardiología en angina inestabla/infarto sin elevación del segmento ST.
Rev Esp Cardiol, 55 (2002), pp. 631-642
[9.]
S. Silber, P. Albertsson, F.F. Aviles, P.G. Camici, A. Colombo, C. Hamm, et al.
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.
Eur Heart J, 26 (2005), pp. 804-847
[10.]
P.J. Loll, D. Picot, R.M. Garavito.
The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase.
Nat Struct Biol, 2 (1995), pp. 637-643
[11.]
C. Patrono.
Aspirin resistance: definition, mechanisms and clinical read-outs.
J Thromb Haemost, 1 (2003), pp. 1710-1713
[12.]
D.J. Schneider.
On defining aspirin resistance.
J Am Coll Cardiol, 46 (2005), pp. 1710-1711
[13.]
U.S. Tantry, K.P. Bliden, P.A. Gurbel.
Resistance to antiplatelet drugs: current status and future research.
Expert Opin Pharmacother, 6 (2005), pp. 2027-2045
[14.]
S.P. Kunapuli, J.L. Daniel.
P2 receptor subtypes in the cardiovascular system.
Biochem J, 336 (1998), pp. 513-523
[15.]
D.C. Mills, R. Puri, C.J. Hu, C. Minniti, G. Grana, M.D. Freedman, et al.
Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase.
Arterioscler Thromb, 12 (1992), pp. 430-436
[16.]
P. Savi, M.C. Laplace, J.P. Maffrand, J.M. Herbert.
Binding of [3H]- 2-methylthio ADP to rat platelets: effect of clopidogrel and ticlopidine.
J Pharmacol Exp Ther, 269 (1994), pp. 772-777
[17.]
I. Müller, M., Rüdiger S. Seyfarth, B. Wolf, G. Pogatsa-Murray, A. Schömig, et al.
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Heart, 85 (2001), pp. 92-93
[18.]
H. Caplain, G. D’Honneur, R. Cariou.
Prolonged heparin administration during clopidogrel treatment in healthy subjects.
Semin Thromb Hemost, 25 (1999), pp. 61-64
[19.]
H. Caplain, F. Donat, C. Gard, J. Necciazi.
Pharmacokinetics of clopidogrel.
Semin Thromb Hemost, 25 (1992), pp. 3-8
[20.]
The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators.
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
N Engl J Med, 345 (2001), pp. 494-502
[21.]
M.S. Sabatine, C.P. Cannon, C.M. Gibson, J.L. Lopez-Sendón, G. Montalescot, P. Theroux.
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
N Engl J Med, 352 (2005), pp. 1179-1189
[22.]
P.A. Gurbel, P. Kevin, K.P. Bliden, K.M. Hayes, J.A. Yoho, W.R. Herzog, et al.
The Relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.
J Am Coll Cardiol, 45 (2005), pp. 1392-1396
[23.]
W. Lau, P.A. Gurbel, P.B. Watkins, C.J. Neer, A.S. Hopp, D.G. Carville, et al.
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance.
Circulation, 109 (2004), pp. 166-171
[24.]
The EPILOG Investigators.
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
N Engl J Med, 336 (1997), pp. 1689-1697
[25.]
R.M. Scarborough.
Development of eptifibatide.
Am Heart J, 138 (1999), pp. 1093-1104
[26.]
The PURSUIT Trial Investigators.
Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
N Engl J Med, 339 (1998), pp. 436-443
[27.]
B.S. Coller.
Anti-GPIIb/IIIa drugs: current strategies and future directions.
Thromb Haemost, 86 (2001), pp. 427-443
[28.]
M. Valgimigli, G. Percoco, D. Barbieri, F. Ferrari, G. Guardigli, G. Parrinello, et al.
The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial.
J Am Coll Cardiol, 44 (2004), pp. 14-19
[29.]
J. Hirsh.
Heparin.
N Engl J Med, 324 (1991), pp. 1565-1574
[30.]
C.B. Granger, J. Hirsh, R.M. Califf, J. Col, H.D. White, A. Betriu, et al.
Activated Partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction : results from the GUSTO-I Trial.
Circulation, 93 (1996), pp. 870-878
[31.]
J. Harenberg, I. Jorg, T. Fanyvesi.
Heparin-induced thrombocytopenia: pathophysiology and new treatment options.
Pathophysiol Haemost Thromb, 32 (2002), pp. 289-294
[32.]
J. Hirsh.
Current anticoagulant therapy: unmet clinical needs.
Thromb Res, 109 (2003), pp. S1-S8
[33.]
The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators.
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
[34.]
J.J. Fergusson, R.M. Califf, E.M. Antman, M. Cohen, C.L. Grines, S. Goodman, et al.
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
Jama, 292 (2004), pp. 45-54
[35.]
D.J. Kereiakes, G. Montalescot, E.M. Antman, M. Cohen, H. Darius, J.J. Ferguson, et al.
Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus.
Am Heart J, 144 (2002), pp. 615-624
[36.]
J.I. Weitz, S.M. Bates.
Acute coronary syndromes: a focus on thrombin.
J Invasive Cardiol, 14 (2002), pp. 2B-7
[37.]
M.A. Parry, J.M. Maraganore, S.R. Stone.
Kinetic mechanism for the interaction of Hirulog with thrombin.
Biochemistry, 33 (1994), pp. 14807-14814
Copyright © 2006. Sociedad Española de Cardiología
Idiomas
Revista Española de Cardiología

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?